Publications by authors named "Jelena Remetic"
Article Synopsis
- The study aimed to use existing laboratory records to identify and treat individuals with hepatitis C virus (HCV) viremia, assisting in broader global elimination efforts.
- Out of 22,682 individuals who tested for HCV-RNA, 6006 had detectable viremia; barriers like invalid contact information hindered follow-up, but efforts led to successful treatment initiation in some.
- This interim report from the ELIMINATE project highlights the potential of systematic screening and recall, identifying a significant number of people previously lost to care who began antiviral treatment.
Background And Aims: Lipopolysaccharide (LPS) clearance is delayed in cholestatic liver diseases. While compromised clearance by Kupffer cells (KCs) is involved, the role of LPS uptake into hepatocytes and canalicular excretion remains unclear.
Approach And Results: Wild-type (WT) and bile salt export pump (Bsep) knockout (KO) mice were challenged i.
Background & Aims: 24-Norursodeoxycholic acid (NorUDCA) is a novel therapeutic bile acid used to treat immune-mediated cholestatic liver diseases, such as primary sclerosing cholangitis (PSC), where dysregulated T cells including CD8 T cells contribute to hepatobiliary immunopathology. We hypothesized that NorUDCA may directly modulate CD8 T cell function thus contributing to its therapeutic efficacy.
Methods: NorUDCA's immunomodulatory effects were first studied in Mdr2 mice, as a cholestatic model of PSC.